… tyrosine kinases in the pathophysiology of GBM and the potential of TKIs in the treatment of
GBM… It also discusses the outcomes of clinical testing of TKIs in glioblastoma patients and the …

… main issues that make GBM treatment challenging … kinase inhibitors were tested as potential
novel therapies [54]. The most disrupted kinases in GBM include receptor tyrosine kinases (…

… ’s potential as an inhibitor lies in its role as a multi-kinase inhibitor, targeting not only …
tyrosine kinase inhibitors (TKI) are investigated in trials to target fusion genes in recurrent GBM …

… The present work discusses the types of gliomas and the molecular mechanism of TKIs,
the physicochemical properties of TKIs required to pass through the BBB, and the …

… be detected after antiangiogenesis drug treatment, either with … tyrosine kinase inhibitors.
Therefore, antiangiogenesis therapies are being increasingly adopted for treating glioblastomas…

… Additionally, the resistance of glioblastoma to axitinib led to an increased number of Treg …
Indeed, machine learning also offers new possibilities to predict the 3D structure of a protein …

… deletion of cyclin-dependent kinase inhibitors (CDKN2A/2B) and … poses a challenge to
currently approved GBM therapies. … has not been examined in GBM, work performed with a variety …

… Small molecule tyrosine kinase inhibitors are the most widely … applicability to GBM presents
more of a challenge. Monoclonal … This work was funded by research funds received from the …

… Citation39 Entrectinib is a selective tyrosine kinase inhibitor of TRK-A, TRK-B and TRK-C, …
, outside the submitted work. The authors report no other conflicts of interest in this work. …

… It has been used in various trials with glioblastoma treatment … to overcome treatment
challenges in glioblastoma, including the … Tyrosine kinase inhibitors (TKIs) inhibit the intracellular …